Eupraxia Pharmaceuticals Inc.
EPRXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeEupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. With a market capitalization of $453.9M, it sits in small-cap territory. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Market Cap
$453.9M
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-6.62
EPS (TTM)
$-1.02
EPS (Fwd)
$-1.04
ROE
-66.7%
ROA
-43.7%
Cash
$133.7M
Total Debt
$1.8M
Free CF
-$18.9M
52W Change
24.2%
Annual Financials
Cash vs Debt
Where EPRX stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, EPRX finished 3.54% above its 150-day moving average ($7.07) and 0.54% below its 200-day moving average ($7.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EPRX overbought or oversold?
At the October 13, 2026 close, EPRX's RSI(14) was 36.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Eupraxia Pharmaceuticals Inc. holds $133.7M in cash against $1.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$18.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -66.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Eupraxia Pharmaceuticals Inc. and its sector.